1. Generics Bulletin
  2. >>Products

Lupin Launches Higher Mirabegron Dose ‘At-Risk’

The 25mg Dose Was Launched Back In April, Also ‘At-Risk’

 
• By Urtė Fultinavičiūtė

Lupin and Zydus have established a two-player market for their generic versions of mirabegron, while patent litigation with originator Astellas continues on.

Person pressing a button which launches a rocket
• Source: Shutterstock

Despite the ongoing litigation with originator Astellas, Lupin decided not to wait around and launch its 50mg generic rival to Myrbetriq (mirabegron).

The launch was hinted at by CEO Vinita Gupta during Lupin’s FY25 Q1 earnings call last month

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

More from Generics Bulletin